Drug intelligence / Profile preview

SRD-1002

Development stage: Preclinical
Lead developer: Medera Group
Modality: Small Molecules
Administration: Oral

Overview

SRD-1002 is a preclinical-stage small molecule therapeutic being developed by Medera Group and its subsidiary, Sardocor, for the treatment of Heart Failure with preserved Ejection Fraction (HFpEF). Administered orally, the drug is part of a broader cardiovascular pipeline aimed at addressing the complex pathophysiology of heart failure. While Medera has not yet disclosed the specific biological target or mechanism of action for SRD-1002, the asset represents the company's small molecule approach to improving cardiac outcomes in HFpEF patients, complementing their gene therapy programs.

Beyond the preview

Go deeper on SRD-1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRD-1002.

Explore the full profile